Role of 0.01% Atropine in Myopia Control of High Myopic Children Of Moradabad (India)

Efficacy of Low Dose Atropine in Prevention of Myopia Progression in Children with High Myopia - CHAMP Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/10/037447

Enrollment

Registered

2021-10-21

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H538- Other visual disturbances

Interventions

Intervention1: Atropine (0.01%): One drop of topical 0.01% atropine daily at bed time for two years Control Intervention1: No Drug or placebo: No drug or placebo

Eligibility

Inclusion criteria

Inclusion criteria: Age: 6 to 16 years Myopia >= 5.00 D (cycloplegic refraction; spherical equivalent) No prior or current treatment for preventing myopia progression

Exclusion criteria

Exclusion criteria: Best corrected visual acuity Refractive Myopia Astigmatism >= 1.5 D Amblyopia Ocular hypertension / Glaucoma Prior intraocular surgery Allergy to atropine eye drops Systemic diseases associated with myopia such as Marfan syndrome, Stickler syndrome History of cardiac or significant respiratory diseases

Design outcomes

Secondary

Measure	Time frame
Change in axial lengthTimepoint: At 1 and 2 years	—

Primary

Measure	Time frame
Progression of Myopia in Diopters (Spherical equivalent relative to baseline)Timepoint: 6 Month, 12 Month, 18 Month, 24 Month, 30 Month and 36 Month	—

Countries

India

Contacts

Public ContactPradeep Agarwal

CL Gupta Eye Institute

drpradeep@clgei.org

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026